Cefditoren pivoxil

Drug Profile

Cefditoren pivoxil

Alternative Names: CDTR-PI; CRTX-062; CRTX-068; ME-1207; Meiact; Spectracef

Latest Information Update: 13 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Cornerstone Therapeutics; Meiji Seika Pharma; Tedec Meiji
  • Class Antibacterials; Cephems; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Bacterial infections; Community-acquired pneumonia; Otitis media; Respiratory tract infections; Skin and soft tissue infections; Tonsillitis
  • Suspended Pharyngitis
  • No development reported Urinary tract infections

Most Recent Events

  • 04 Feb 2014 Cornerstone Therapeutics has been acquired by Chiesi Farmaceutici
  • 31 Mar 2011 Phase-III clinical trials in Bacterial infections (in children) in Japan (PO, Granules)
  • 01 Oct 2010 Meiji Seika Pharma initiates enrolment a phase III trial in Community-acquired pneumonia in Japan (PO) (JapicCTI-101300)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top